This site is intended for healthcare professionals

TRuE-AD2 pivotal trial of ruxolitinib cream met its primary endpoint in patients with atopic dermatitis.- Incyte Corpn.

Read time: 1 mins
Published:29th Jan 2020
Incyte announced positive topline results from its randomized, vehicle-controlled, pivotal Phase III TRuE-AD2 study evaluating the safety and efficacy of ruxolitinib cream in adolescent and adult patients (age greater than 12 years) with atopic dermatitis (AD). The study, part of the TRuE-AD clinical trial program, met its primary endpoint. Significantly more patients treated with ruxolitinib cream 0.75% and 1.5% achieved Investigator’s Global Assessment Treatment Success (IGA-TS) – defined as an IGA score of 0 (clear) or 1 (almost clear) with at least a two-point improvement from baseline at Week 8 – than patients treated with vehicle control (non-medicated cream). The overall efficacy and safety profile of ruxolitinib cream is consistent with previous data, and no new safety signals were observed. The long-term safety portion of the study will continue as planned. Data from TRuE-AD2 will be submitted for presentation at an upcoming scientific meeting.
Condition: Atopic Dermatitis (Eczema)
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.